Skip to main content Deutsch


Ovarian Cancer Therapy - Innovative Models Prolong Survival

Identification and validation molecules and pathways responsible for relapse

About 75% of advanced epithelial ovarian cancer (EOC) patients respond to first-line surgery and chemotherapy but most relapse and ultimately acquire platinum resistance which soon leads to death.

Relapsed high grade serous ovarian cancer (HGSOC) is the single main cause of EOC-related morbidity and mortality. We hypothesize that the primary tumour includes a small population of resistant cells that are ultimately responsible for relapse. By targeting this population front-line we may prolong disease-free survival or even achieve cure. OCTIPS will use unique retrospective and novel prospective paired tumour samples collected at the time of diagnosis and relapse to identify and validate molecules and pathways responsible for relapse. This identification will employ high throughput multiplatform analyses such as next generation sequencing, mRNA and miRNA  expression arrays and SNP array. Known and newly defined molecules or pathways will be evaluated in innovative integrated cancer model systems like cell lines, avian egg and murine xenografts. New therapies targeting these molecules and pathways will be developed and validated in model systems. 

By translating the clinical observation of treatment failures into innovative cancer models that mimic relapsed ovarian cancer, we will validate improved front-line therapeutic strategies to help prolong patient survival.

Researchers of the Medical University

The Medical University of Vienna is project coordinator under the leadership of Ao. Univ.-Prof. Dr. Dan Cacsire Castillo-Tong, Department of Obstetrics and Gynecology.

Ao. Univ.-Prof. Dr. Dan Cacsire Castillo-Tong

Head of project

Department of Obstetrics and Gynecology

Further participating department at the edical University of Vienna:
Ao. Univ.-Prof. Georg Heinze, CeMSIIS, Institut für Klinische Biometrie


Project coordinator: Ao. Univ.-Prof. Dr. Dan Cacsire Castillo-Tong, Universitätsklinik für Frauenheilkunde, MedUni Vienna

Project partners: 11


TopicHEALTH.2011.2.4.1-2: Translational research on cancers with poor prognosis, FP7-HEALTH-2011-two-stage
Project duration01.01.2012 - 31.12.2015
Funding volume, total2.999.302 €
Funding volume, Medical University of Vienne533.492 € 


The OCTIPS project under the leadership of Univ.-Prof. Dr. Dan Cacsire Castillo-Tong is devoted to identifing a validation of molecular signatures of relapsing ovarial cancer, in order to develop new treatements against the disease. Find out more on the official OCTIPS website!